Dr. Chapa’s OBGYN Clinical Pearls

Dr. Chapa’s Clinical Pearls
undefined
Nov 17, 2025 • 31min

More Measles Material

This discussion dives deep into the impacts of measles during pregnancy. It outlines the critical 'rule of four' for infectious periods and highlights risks like pneumonia and fetal complications. Listeners will learn about diagnostic signs, including the infamous Koplik spots, and how timing can influence outcomes. The podcast also clarifies that measles isn't a known teratogen and addresses concerns regarding breastfeeding and newborn protection. Plus, insights on vaccination timing for nonpregnant contacts make it a vital listen!
undefined
Nov 12, 2025 • 18min

Self-Hypnosis For Hot Flash Relief.

The term "hypnosis" was first described in 1843 byScottish surgeon James Braid, who published the book Neurypnology. He coined the term "hypnosis" from the Greek word for sleep to describe the trance-like state induced by focusing on a bright object. Self-hypnosis has nowbeen shown to aid in menopausal hot flash reduction! In this episode, we will review this brand new publication from JAMA Network which confirmed via a multicenter RCT that a simple daily hypnosis audio session was effective forsymptom relief. The study is the first to compare self-guided hypnosis with an active control condition (i.e. sham white noise control group). Listen in for details. 1.     Elkins G, Arring N, Morgan G, Lorenz T, Muniz V,Lafferty C, Scheffrahn K, Alldredge C, Barton D. Self-Administered Hypnosis vsSham Hypnosis for Hot Flashes: A Randomized Clinical Trial. JAMA Netw Open.2025 Nov 3;8(11):e2542537. doi: 10.1001/jamanetworkopen.2025.42537. PMID:41217756.2.     https://interestingengineering.com/health/hypnosis-lowers-menopause-hot-flashes 
undefined
Nov 12, 2025 • 32min

That's So Random!

Well, from time to time we cover RANDOM tidbits of information which cover RANDOM questions and/or RANDOM patient care issues that we encounter. In this episode we will cover one OB issue related to recurrent pregnancy loss, one GYN issue related to unilateral breast swelling in a patient with SLE, and one RANDOM life perspective response from a mock interview that I participated in for a residency candidate. Listen in fordetails!1.     Viviana DO; Giugni, Claudio Schenone MD; Ros, Stephanie T. MD, MSCI. Factor V and recurrent pregnancy loss: de Assis, Evaluation of Recurrent Pregnancy Loss. Obstetrics & Gynecology 143(5):p 645-659, May 2024. | DOI: 10.1097/AOG.0000000000005498Unilateral Breast Swelling with SLE: 2.     Voizard B, Lalonde L, Sanchez LM, et al. LupusMastitis as a First Manifestation of Systemic Disease: About Two Cases With a Review of the Literature. European Journal of Radiology. 2017;92:124-131. doi:10.1016/j.ejrad.2017.04.023.3.     Kinonen C, Gattuso P, Reddy VB. Lupus Mastitis:An Uncommon Complication of Systemic or Discoid Lupus. The American Journal of Surgical Pathology. 2010;34(6):901-6. doi:10.1097/PAS.0b013e3181da00fb.4.      Summers TA, Lehman MB, Barner R, Royer MC. Lupus Mastitis: A Clinicopathologic Review and Addition of a Case. Advances in Anatomic Pathology.2009;16(1):56-61. doi:10.1097/PAP.0b013e3181915ff7.5.     Jiménez-Antón A, Jiménez-Gallo D,Millán-Cayetano JF, Navarro-Navarro I, Linares-Barrios M. Unilateral Lupus Mastitis.Lupus. 2023;32(3):438-440. doi:10.1177/09612033221151011.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG
undefined
Nov 10, 2025 • 15min

HISTORY MADE: New HRT News TODAY (11/10/25)

On August 15, 2025, we reviewed the data from an FDA expert panel calling on the FDA to remove the exiting Black Box warning on commercial HRT options for menopausal care. In a historic decision, this happened today. Listen in for details! 1. https://www.cbsnews.com/video/fda-chief-explains-changes-to-black-box-warnings-on-some-hormone-therapies-for-menopause/2. https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html
undefined
Nov 9, 2025 • 24min

A BMI-Based Labor Curve?

The ACOG acknowledges that maternal obesity affects labor curves and recommends allowing more time for cervical dilation before diagnosing labor arrest in obese patients. This approach aims to avoid unnecessary interventions, such as premature cesarean delivery, which may occur if standard labor curves are strictly applied to obese women. In this episode, we will review a new study from the AJOG (08 Nov 2025) which describes labor progression and duration according to maternal body mass index, validating the need (possibly) for a BMI -based labor curve. Has there been advocates of a BMI-based labor curve? Listen in for details.1. Edwards, Sara et al. Characterizing Labor Progression and Duration According to Maternal Body Mass Index. American Journal of Obstetrics & Gynecology, Volume 0, Issue 02. Lundborg L, Liu X, Åberg K, et al. Association of Body Mass Index and Maternal Age With First Stage Duration of Labour. Scientific Reports. 2021;11(1):13843. doi:10.1038/s41598-021-93217-5.3. Kominiarek MA, Zhang J, Vanveldhuisen P, et al. Contemporary Labor Patterns: The Impact of Maternal Body Mass Index. American Journal of Obstetrics and Gynecology. 2011;205(3):244.e1-8. doi:10.1016/j.ajog.2011.06.014.4. Norman SM, Tuuli MG, Odibo AO, et al. The Effects of Obesity on the First Stage of Labor.Obstetrics and Gynecology. 2012;120(1):130-5. doi:10.1097/AOG.0b013e318259589c.
undefined
Nov 6, 2025 • 28min

Use Antibiotics at 2nd Degree OB Lac Repair?

The podcast dives into the controversial use of prophylactic antibiotics during second-degree laceration repairs. It evaluates the latest BMJ randomized trial and a meta-analysis revealing mixed evidence on infection rates. Dr. Chapa discusses why recommendations often lag behind emerging data and contrasts protocols for more severe injuries. He also shares insights on practical applications for high-risk patients. Ultimately, a modest benefit for antibiotics is identified, but universal use remains unadvised.
undefined
Nov 5, 2025 • 31min

“New” PCOS Info: 4 Types (AGAIN)

Explore the complexities of polycystic ovary syndrome (PCOS) as experts discuss four distinct phenotypes. Discover how new research largely reconfirms existing classifications and the implications for IVF and pregnancy outcomes. Learn that not all PCOS patients experience insulin resistance and that traditional views may overlook critical differences. Delve into lab-based subtypes and the importance of individualized care in managing this heterogeneous condition.
undefined
Nov 2, 2025 • 29min

Folic Acid Update: Women on Epilepsy Meds Do NOT Need More

Discover the latest updates on folic acid recommendations for women on anti-seizure medications. High doses are no longer the standard, shifting from 4-5 mg to a safer range of 400-800 mcg. Dr. Chapa highlights research suggesting that additional folate may not reduce risks for neural tube defects linked to certain epilepsy drugs. International guidelines are changing too, as countries adopt lower dosing. Tune in for crucial insights that impact clinical practices and patient care during pregnancy.
undefined
Oct 31, 2025 • 21min

Whole Blood for PPH!

Back on August 9, 2024, we released an episode (link in the show notes) reviewing the renewed interest in transfusing whole blood for PPH rather than component therapy. Now, in O&G open, authors from my Alma Mater (UT Southwestern) have published new data bolstering the use of whole blood for PPH. Listen in for details.1. Clinical Pearls Episode 2024: https://open.spotify.com/episode/0ZhqoIE9wMcAboDlevq9OW?si=rM32uK8ER8uuWmq4mf5dzA2. Ambia, Anne M. MD; Burns, R. Nicholas MD; White, Alesha MD; Warncke, Kristen MD; Gorman, April MS; Duryea, Elaine MD; Nelson, David B. MD. Whole Blood in the Management of Postpartum Hemorrhage. O&G Open 2(5):e130, October 2025. | DOI: 10.1097/og9.00000000000001303. ACPG PB 183STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG
undefined
Oct 29, 2025 • 22min

New Med For Hot Flashes

Elinzanetant, sold under the brand name Lynkuet, receivedapproval from the U.S. Food and Drug Administration (FDA) on October 24, 2025, for the treatment of moderate to severe hot flashes due to menopause.  How is this different than Fezolinetant, which was approved in 2023? Listen in for details. 1.   Menegaz de Almeida, Artur MS; Oliveira, Paloma MS; Lopes, Lucca MD; Leite, Marianna MS; Morbach, Victória MS; Alves Kelly, Francinny MD; Barros, Ítalo MS; Aquino de Moraes, Francisco Cezar MS; Prevedello, Alexandra MD. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstetrics & Gynecology 145(3):p 253-261, March 2025. | DOI: 10.1097/AOG.00000000000058122.     Pinkerton JV, Simon JA, Joffe H, Maki PM, NappiRE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343–54. doi: 10.1001/jama.2024.14618. Epub ahead of print. PMID: 39172446; PMCID: PMC11342219.3.     Cardoso F, Parke S, Brennan DJ, Briggs P,Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptomsfrom Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. PMID: 40454634.STRONG COFFEE PROMO: 20% Off Strong CoffeeCompany https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app